Bionano Genomics (BNGO)
(Real Time Quote from BATS)
$0.75 USD
-0.01 (-1.46%)
Updated Apr 25, 2024 12:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Bionano Genomics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 102 | 113 | 251 | 38 | 17 |
Receivables | 9 | 7 | 5 | 3 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 23 | 30 | 12 | 3 | 3 |
Other Current Assets | 6 | 7 | 4 | 2 | 1 |
Total Current Assets | 140 | 157 | 272 | 47 | 28 |
Net Property & Equipment | 23 | 18 | 10 | 5 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 34 | 118 | 83 | 9 | 0 |
Deposits & Other Assets | 8 | 3 | 1 | 0 | 0 |
Total Assets | 214 | 308 | 377 | 60 | 30 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 70 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 13 | 10 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 20 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 11 | 10 | 6 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 10 | 1 | 0 | 0 |
Total Current Liabilities | 100 | 36 | 22 | 9 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 16 | 0 |
Non-Current Capital Leases | 4 | 4 | 4 | 0 | 0 |
Other Non-Current Liabilities | 11 | 13 | 9 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 118 | 58 | 40 | 25 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 677 | 599 | 554 | 179 | 106 |
Retained Earnings | -581 | -349 | -216 | -144 | -103 |
Other Equity | 0 | -1 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 96 | 249 | 337 | 35 | 4 |
Total Liabilities & Shareholder's Equity | 214 | 308 | 377 | 60 | 30 |
Total Common Equity | 96 | 249 | 337 | 35 | 4 |
Shares Outstanding | 45.70 | 29.60 | 28.90 | 19.00 | 3.40 |
Book Value Per Share | 2.10 | 8.43 | 11.67 | 1.85 | 1.06 |
Fiscal Year End for Bionano Genomics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 102 | 64 | 77 | 96 |
Receivables | NA | 9 | 9 | 8 | 7 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 23 | 26 | 32 | 33 |
Other Current Assets | NA | 6 | 6 | 5 | 7 |
Total Current Assets | NA | 140 | 105 | 123 | 143 |
Net Property & Equipment | NA | 23 | 21 | 20 | 19 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 34 | 36 | 115 | 117 |
Deposits & Other Assets | NA | 8 | 11 | 3 | 3 |
Total Assets | NA | 214 | 182 | 271 | 292 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 70 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 15 | 12 | 16 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 12 | 8 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 9 | 11 | 11 | 11 |
Total Current Liabilities | NA | 100 | 40 | 34 | 38 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 4 | 4 | 4 | 4 |
Other Non-Current Liabilities | NA | 15 | 15 | 14 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 118 | 63 | 57 | 61 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 677 | 656 | 640 | 618 |
Retained Earnings | NA | -581 | -537 | -425 | -386 |
Other Equity | NA | 0 | 0 | 0 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 96 | 119 | 215 | 231 |
Total Liabilities & Shareholder's Equity | NA | 214 | 182 | 271 | 292 |
Total Common Equity | 0 | 96 | 119 | 215 | 231 |
Shares Outstanding | 54.60 | 45.70 | 35.30 | 30.60 | 30.60 |
Book Value Per Share | 0.00 | 2.10 | 3.37 | 7.02 | 7.57 |